{
    "nctId": "NCT05807516",
    "briefTitle": "Single-cell RNAseq Breast Cancer",
    "officialTitle": "Study of the Impact of Neoadjuvant Therapy on the Heterogeneity of Triple Negative Breast Cancer Through Single-cell RNA Sequencing (scRNAseq) and Whole-exome Sequencing (WES)",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Neoplasms",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Evaluate chemoterapy effect",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with histologically proven primary invasive breast cancer \\>1.5cm in size, with molecular assessed stage IIA to IIIB defined as TNBC, and who will undergo neoadjuvant chemotherapy and subsequent surgery (and/or have undergone - retrospective part).\n* informed consent (prospective part)\n\nExclusion Criteria:\n\n* pregnancy, metastatic breast cancer, previous chemotherapy, hormone therapy, radiation therapy, previous other cancers or contralateral breast cancer",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}